Pure Global
NCT06384807

A Phase 1/2 Study of PBI-410 in Advanced Solid Tumors

A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of PBI-410 in Participants With Advanced Solid Tumors
Pyramid Biosciences·Phase 1/2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
PBI-410
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Pyramid Biosciences
Location
Dallas,West Valley City,Fairfax, United States of America
Timeline & enrollment
Phase
Phase 1/2
Start date
Apr 01, 2024
End date
Feb 01, 2028
Enrollment
170 participants
Primary outcome

Phase 1: Number of patients with adverse events (AEs),Phase 1: Recommended dose for expansion (RDE) and maximum tolerated dose (MTD),Phase 2: Objective Response Rate (ORR),Phase 2: Number of patients with AEs,Phase 2: Duration of Response (DoR)

Summary

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of PBI-410 in
 participants with previously treated, advanced solid tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06384807
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06384807 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Pyramid Biosciences and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 170 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.